Studied MOTS-c Dosage Ranges
FIG. IV · DOSAGE RECORD / GAUGE BANK
Three gauges: rodent preclinical range (0.5–15 mg/kg), self-experiment self-report (5–10 mg/week SC), and the therapeutic gauge — uncalibrated, no established dose.
MOTS-c dosage in the peer-reviewed literature spans a wide range depending on model and endpoint.
| Model | Dose | Route | Duration | Study |
|---|---|---|---|---|
| Diet-induced obese mice (metabolic) | 15 mg/kg/day | Intraperitoneal | Chronic | Lee 2015[1] |
| Diet-induced obese mice (low-dose arm) | 2.5 mg/kg/day | Intraperitoneal | Chronic | Lee 2015[1] |
| Obese mice (metabolomics) | 2.5 mg/kg BID | Intraperitoneal | 3 days | Kim 2019[5] |
| Aged mice (healthspan/endurance) | 5 mg/kg 3×/week | Subcutaneous | Chronic late-life | Reynolds 2021[2] |
| Cardiac pressure-overload mice | 5 mg/kg/day | SC (osmotic pump) | 4 weeks | Zhong 2022[10] |
| Type-2-diabetic rats (cardiac) | 15 mg/kg/day | Intraperitoneal | 3 weeks | Pham 2025[11] |
| Human myotubes (in vitro) | 10 µM | Culture media | — | Elhusseiny 2026[13] |
NO THERAPEUTIC DOSE ESTABLISHED
No therapeutic dose has been established in a controlled clinical trial. Human self-experiment protocols reported in wellness communities typically cite 5–10 mg/week subcutaneous, but these are not from peer-reviewed trials. MOTS-c dosage for humans is not validated.
MOTS-c Half-Life and Pharmacokinetics
Formal pharmacokinetic half-life data for exogenous subcutaneous MOTS-c administration have not been published as of 2025 — neither in humans nor as a standalone rodent PK paper.
What the literature does show: human exercise induces an 11.9-fold increase in skeletal muscle MOTS-c expression and a 1.5–1.6-fold rise in circulating plasma MOTS-c, with levels returning toward baseline within approximately four hours post-exercise.[3] This documents the elimination timecourse for endogenously induced MOTS-c in humans, not for an exogenous subcutaneous dose.
For exogenous administration: published efficacy studies used subcutaneous osmotic pumps (continuous delivery) or injection protocols of 3–15 mg/kg administered multiple times per week or daily in rodents — protocols designed to maintain sustained exposure rather than characterize plasma half-life.[2][10] No plasma concentration-time curve data are available.
The inference from available data is a short plasma half-life consistent with a 16-amino-acid peptide subject to proteolytic degradation. Validated PK characterization in humans has not been published.
Oral vs Subcutaneous Delivery
Subcutaneous injection is the route used in virtually all published efficacy studies. MOTS-c as a 16-amino-acid peptide is subject to rapid proteolytic degradation in the gastrointestinal tract.
Some animal studies explored oral delivery at higher doses, but oral bioavailability has not been validated against subcutaneous exposure in comparative PK studies. Intraperitoneal injection was the most common route in early rodent studies; subcutaneous injection (including osmotic pump delivery) became dominant in later work to improve translational relevance.[2][10]
Reconstitution and Storage of Research-Grade MOTS-c
RESEARCH CONTEXT
Research-Grade Chemical Reagent
This represents the reconstitution approach described in research protocols. Research-grade MOTS-c is a chemical reagent, not a pharmaceutical product.
Lyophilized (freeze-dried) MOTS-c is stable for extended periods at -20°C. Typical reconstitution in research protocols uses bacteriostatic water at 1–2 mL per 10 mg vial, producing a solution of 5–10 mg/mL. Reconstituted solutions are stored at 4°C and used within a short window to prevent degradation. Repeated freeze-thaw cycles reduce peptide integrity.
Administration Timing in the Research Literature
Mouse studies administered MOTS-c subcutaneously before treadmill exercise sessions in the endurance arm of Reynolds et al. 2021.[2] The late-life healthspan arm used a three-times-weekly schedule independent of exercise timing.
No circadian or meal-timing optimization data from human trials exist. No peer-reviewed study has examined pre-workout versus fasted versus post-meal MOTS-c administration in humans.
Onset of Effects: Research Timeframes
Rodent studies show metabolic improvements within the first few weeks of daily MOTS-c administration. In the Lee 2015 chronic obesity study, insulin sensitivity and glucose tolerance improvements were measurable after two to four weeks of treatment.[1]
The acute metabolomics study (2.5 mg/kg BID for three days) showed measurable plasma metabolite changes within 72 hours.[5]
No controlled human trial has characterized time-to-effect for exogenously administered MOTS-c.
MOTS-c Combined with GLP-1 Receptor Agonists
No controlled study has examined MOTS-c combined with GLP-1 receptor agonists. Mechanistically the two act on different pathways: MOTS-c operates via the mitochondrial folate-AICAR-AMPK axis, while GLP-1 agonists operate via incretin signaling (GLP-1R, cAMP/PKA). There is no published mechanistic or pharmacokinetic basis for predicting interaction. Combination use is anecdotal.
MOTS-c Stacking: What Research Exists
Published stacking data for MOTS-c are absent from the peer-reviewed literature.
SS-31 (elamipretide) is sometimes cited alongside MOTS-c in self-experiment reports targeting mitochondrial health. SS-31 is a mitochondria-targeted tetrapeptide that stabilizes cardiolipin on the inner mitochondrial membrane — complementary in pathway (membrane integrity vs metabolic regulation), but no controlled study has examined the combination.
For MOTS-c and metformin: both activate AMPK. Their upstream mechanisms partially overlap (metformin inhibits mitochondrial Complex I, raising AMP/ATP ratio; MOTS-c inhibits folate-purine synthesis to accumulate AICAR). Theoretically additive but potentially redundant — and the combination could increase the risk of excessive AMPK activation. See MOTS-c and Metformin: Overlapping Mechanisms on the FAQ page.
MOTS-c and Metformin: Overlapping Mechanisms
Both MOTS-c and metformin activate AMPK, though via different upstream mechanisms. Metformin inhibits mitochondrial Complex I, raising the AMP/ATP ratio and activating AMPK. MOTS-c inhibits the folate cycle, accumulating AICAR to activate AMPK.[1][17]
The overlap is mechanistically significant: in insulin-resistant individuals already taking metformin, adding exogenous MOTS-c would apply additional AMPK activation on top of the existing pharmacological effect. No controlled human study has examined the combination. The theoretical concern — excessive AMPK activation and risk of hypoglycemia — has not been characterized in any published study.